<DOC>
	<DOCNO>NCT02285062</DOCNO>
	<brief_summary>To evaluate efficacy safety lenalidomide , rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ( R2-CHOP ) chemotherapy versus placebo , rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ( placebo-R-CHOP ) chemotherapy patient previously untreated ABC type DLBCL .</brief_summary>
	<brief_title>Efficacy Safety Study Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy Untreated ABC Type Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>This research study patient newly diagnose Diffuse Large B-cell Lymphoma ( DLBCL ) activate B-cell ( ABC ) type yet treat . DLBCL cancer type blood cell call B-lymphocytes . B lymphocytes part body 's immune system . There different type DLBCL . About third newly diagnose DLBCL cancer ABC type . It observe treatment work well patient ABC type compare patient DLBCL type receive standard treatment . However , time ABC type DLBCL type patient receive standard treatment . Patients DLBCL otherwise healthy usually treat first chemotherapy drug combination call R-CHOP . The drug combination `` R '' rituximab , `` C '' cyclophosphamide , `` H '' doxorubicin chemical name hydroxydaunomycin , `` O '' vincristine trade name oncovin , `` P '' prednisone . Depending local practice treat , R-CHOP may give 6 8 cycle . A cycle could last 14 21 day . The R-CHOP drug combination approve treatment DLBCL type , include ABC type . R-CHOP standard care . This study test standard R-CHOP21 R-CHOP21 plus lenalidomide . The purpose see whether add lenalidomide work well safe R-CHOP . This study patient ABC type DLBCL yet treat . Lenalidomide approve use DLBCL . Its use disease experimental . In study , experimental treatment lenalidomide + R-CHOP21 x 6 . This study use gene expression profile ( GEP ) test see patient ABC type . The result GEP test affect whether may treat study . Because performance test proven , investigational use , still development . This mean GEP test experimental test .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Histologically proven Diffuse Large BCell Lymphoma Activated BCell type 2 . Newly diagnose , previously untreated Diffuse Large BCell Lymphoma 3 . Measurable Diffuse Large BCell Lymphoma disease Computed Tomography ( CT ) / Magnetic Resonance Imagining ( MRI ) scan 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 5 . Age 18 80 year ; age &gt; 80 allow investigator discretion performance status ≤ 1 ; organ system score ≤ 2 use cumulative illness rating scale ( CIRS ) 1 . Diagnosis lymphoma histology Diffuse Large BCell Lymphoma 2 . History malignancy , Diffuse Large BCell Lymphoma , unless patient disease free 5 year 3 . Known seropositive , history , active Human Immunodeficiency Virus ( HIV ) Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) 4 . Contraindication drug chemotherapy regimen , specifically : LVEF ( Left Ventricular Ejection Fraction ) &lt; 45 % peripheral neuropathy grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>R-CHOP chemotherapy</keyword>
	<keyword>DLBCL front line therapy</keyword>
	<keyword>gene expression profile ( GEP ) activate B-cell ( ABC ) type DLBCL biomarkers</keyword>
	<keyword>Activated B-Cell ( ABC ) type</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma , otherwise specify</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma , associate chronic inflammation</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma , Epstein-Barr virus positive ( EBS+ ) elderly</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma , T-cell / histiocyte-rich</keyword>
</DOC>